Biased Ligands. Better Drugs.

Trevena to Present at the Cowen and Company 38th Annual Healthcare Conference
3/7/18

Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Cowen and Company 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 8:40 a.m. ET in Boston, MA.

To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain.  The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain.  OLINVO has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications. 

Contacts

Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
jviolin@trevena.com

Media
Public Relations 
PR@trevena.com

Copyright © Trevena, Inc.